Physician profile
Bryan Ferroni
NPI 1508836339
$37,685.26
in general payments reported to CMS, 2019-2025
42 companies · $2,089 in 2025
The $2,089 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $13K · 2021: $1,651 · 2022: $2,030 · 2023: $2,180 · 2024: $1,217 · 2025: $2,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,486.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $14,608.22 | 2019 | |
| Mallinckrodt Hospital Products INC. | $11,007.22 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $2,837.54 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,592.54 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mylan Specialty L.P. | $1,010.19 | 2019-2024 | Yupelri |
| Genzyme Corporation | $969.18 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $595.89 | 2019-2025 | Dupixent |
| Ani Pharmaceuticals, INC. | $541.32 | 2023-2024 | Purified Cortrophin Gel |
| Harmony Biosciences LLC | $519.40 | 2020-2025 | Wakix |
| Sunovion Pharmaceuticals INC. | $486.46 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.44 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Amgen INC. | $360.52 | 2022-2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $356.47 | 2019-2025 | |
| Axsome Therapeutics, INC. | $321.62 | 2023-2025 | Sunosi |
| Insmed, INC. | $320.01 | 2019-2025 | Arikayce |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $283.73 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy, Patient Interface Software |
| Genentech USA, INC. | $197.91 | 2019-2025 | Xolair |
| Grifols USA, LLC | $193.93 | 2019-2024 | Prolastin-C Liquid |
| Verona Pharma, INC. | $174.08 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $152.58 | 2019-2025 | Tyvaso, Tyvaso |
| Avadel Cns Pharmaceuticals, LLC | $134.12 | 2023-2025 | Lumryz |
| Novartis Pharmaceuticals Corporation | $88.73 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $68.53 | 2019-2023 | Airduo Digihaler |
| Paratek Pharmaceuticals, INC. | $43.72 | 2024-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $40.92 | 2021-2022 | |
| Advanced Respiratory, INC | $39.97 | 2019-2021 | |
| Covis Pharma Gmbh | $37.39 | 2021-2022 | |
| Vifor Pharma, INC. | $32.65 | 2025 | Veltassa, Zemaira |
| Gilead Sciences, INC. | $31.39 | 2019-2025 | Veklury |
| Bayer Healthcare Pharmaceuticals INC. | $30.33 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $29.02 | 2019-2021 | |
| Csl Behring | $27.30 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $26.21 | 2021 | |
| Bio Products Laboratory USA, INC. | $24.55 | 2020-2021 | |
| Phadia US INC. | $22.12 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.31 | 2025 | Alvesco |
| Electromed, INC. | $15.52 | 2024 | Smartvest |
| Lilly USA, LLC | $14.64 | 2025 | Mounjaro, Zepbound |
| Shire North American Group INC | $14.39 | 2019 | |
| Adma Biomanufacturing LLC | $14.16 | 2022 | |
| Pfizer INC. | $13.77 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Ferroni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.